McLaren Health Care is proud to be among the first health systems in the United States selected for a ground-breaking clinical trial for AIRSUPRA, ™ the first inhaler approved for as-needed use to reduce asthma exacerbation risks. This inhaler combines albuterol and budesonide, offering dual action: albuterol relaxes airway muscles for easier breathing, while budesonide reduces lung inflammation.
Participants in the ANCHOR trial must be 18 years of age, have asthma, and are prescribed an albuterol only or levalbuterol short-acting inhaler for rescue use. The trial aims to assess asthma exacerbation rates when patients switch from traditional albuterol or levalbuterol inhalers to AIRSUPRA. What sets this study apart is its virtual format, eliminating the need for in person visits; all interactions will occur via phone or email.
Eligible participants who consent to join will receive a prescription card, allowing them to obtain AIRSUPRA at no cost throughout the 12-month period. The study team will contact patients every three months to collect relevant information. Clinics interested in offering this trial can have a dedicated liaison visit to provide study materials and answer questions about AIRSUPRA.
For more information or to refer patients, clinicians can call 1-844-ANCHOR-0, text (248) 748-9971, or email [email protected]. Visit mclaren.org/anchorstudy for more information about the study.